The surge in market value is largely attributed to the integration of placenta extracts into high-end skincare, including creams, serums, and anti-aging formulations. While porcine placenta remains the primary source material, the industry is increasingly diversifying into equine and ovine sources to meet the needs of the cosmetic, dietary supplement, and pharmaceutical sectors. Manufacturers are currently focusing on refining extraction technologies to produce versatile powder, liquid, and gel formats.

Asia-Pacific currently holds the dominant share of the global landscape, anchored by robust research ecosystems in Japan, South Korea, and China. Despite the positive trajectory, the sector faces headwinds from complex regulatory environments and ethical debates surrounding animal-derived sourcing. Companies such as MiMedx Group, Japan Bio Products, and Smith & Nephew are navigating these challenges by prioritizing product standardization and expanding their presence in emerging markets across the Middle East and South America.